Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177242 · ClinicalTrials.gov registry record · Phase 2
Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00177242 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 45 participants.
The verdict
NCT00177242, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a phase II, open-label trial of Gefitinib and docetaxel in patients having one prior regimen of chemotherapy for with metastatic pancreatic carcinoma.
Interventions
- DRUG Gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177242
The ClinicalTrials.gov registry entry for NCT00177242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gefitinib is the first listed.
NCT00177242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00177242 about?
NCT00177242 is a clinical study titled "Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma". This is a phase II, open-label trial of Gefitinib and docetaxel in patients having one prior regimen of chemotherapy for with metastatic pancreatic carcinoma.
What is the current status of trial NCT00177242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2004-09. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00177242?
The interventions under investigation include: Gefitinib (DRUG).
Who is sponsoring clinical trial NCT00177242?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.